Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis

Final draft guidance:  TA1018

Final draft guidance (PDF 226 KB)

Committee papers (PDF 8.94 MB)

Public committee slides (PDF 1.04 MB)

Equality impact assessment (downloadable version) (PDF 139 KB)

Register of interests (MSWord 52 KB)

Final scope (PDF 201 KB)

Final stakeholder list (PDF 202 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 126 KB)

Equality impact assessment (Scoping) (PDF 125 KB)

Draft scope post referral (PDF 208 KB)

Draft matrix of consultees and commentators post referral (PDF 192 KB)

Equality impact assessment (guidance development): TA756 (PDF 153 KB)

Register of interests: TA756 (PDF 155 KB)

Final draft guidance: TA756 (PDF 297 KB)

Final appraisal document - Managed Access Agreement: TA756 (PDF 351 KB)

Committee papers: TA756 (PDF 1.46 MB)

Public committee slides: TA756 (PDF 717 KB)

Draft guidance (downloadable version): TA756 (PDF 314 KB)

Committee papers: TA756 (PDF 4.57 MB)

Public committee slides: TA756 (PDF 1.11 MB)

Final scope: TA756 (PDF 171 KB)

Final stakeholder list: TA756 (PDF 192 KB)

NICE's response to comments on the draft scope and provisional stakeholder list: TA756 (PDF 167 KB)

Equality impact assessment (scoping): TA756 (PDF 122 KB)

Draft scope post referral: TA756 (PDF 206 KB)

Draft matrix post referral: TA756 (PDF 190 KB)